amoxicillin-potassium-clavulanate-combination and Spondylitis--Ankylosing

This article presents the efficacy of co-amoxiclav in two patients with ankylosing spondylitis. Both patients were administered oral co-amoxiclav for 7 days. The primary efficacy variable was the ankylosing spondylitis activity index. Secondary outcome measures were the ankylosing spondylitis functional index and spinal mobility. We detected a marked improvement in all symptoms and physical examination parameters. Co-amoxiclav has been shown to be effective against ankylosing spondylitis.

Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Humans; Spondylitis, Ankylosing; Time Factors; Treatment Outcome

To describe a case of orbital cellulitis arising in a patient treated with an anti-TNFalpha agent.. Single interventional case report.. A 42-year-old man developed severe unilateral orbital cellulitis while receiving infliximab (Remicade, Centocor) treatment for Ankylosing spondylitis (AS) as part of the open-label phase of a trial conducted at our tertiary referral center. Cultures grew Staphylococcus aureus.. Infliximab treatment was stopped and the patient made a full recovery after receiving appropriate antibiotic therapy. Infliximab therapy was resumed after three weeks.. Clinical vigilance is warranted when treating patients with anti-TNFalpha agents as these are associated with a diverse and growing number of ophthalmic complications. Resolved infection does not preclude the use of such agents.

Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antibodies, Monoclonal; Cefotaxime; Cellulitis; Drug Therapy, Combination; Eye Infections, Bacterial; Humans; Infliximab; Male; Microbial Sensitivity Tests; Orbital Diseases; Randomized Controlled Trials as Topic; Spondylitis, Ankylosing; Staphylococcal Infections; Staphylococcus aureus; Tumor Necrosis Factor-alpha